An Update on Disease of the Esophagus and on IBD

All Lectures will be 20 minutes with 10 minutes for discussion

MORNING SESSION
Morning session moderator: Alexandra Ilnyckyj

0825-0830 Welcome  
Charles Bernstein

0830-0930 Progress in achalasia evaluation and management  
Marcelo Vela

0900-0930 GERD  
Ronnie Fass

0930-1000 Eosinophilic Esophagitis  
David Katzka

1000-1030 Management of Barrett’s esophagus  
Sachin Wani

1030-1050 break

1050-1120 Discontinuing Long Term PPI Use—Why, With Whom and How?  
Laura Targownik

1120-1220 Panel discussion  
Alexandra Ilnyckyj

1220-1320 Lunch

AFTERNOON SESSION
Afternoon session moderator: Charles Bernstein

1320-1350 Psychosocial support for IBD patients – a specialty medical home perspective  
Miguel Regueiro

1350-1420 Choosing a biologic in Crohn’s disease  
John Marshall

1420-1440 Choosing a biologic in UC  
Reena Khanna

1440-1500 break

1500-1530 Approach to fistulas in Crohn’s  
Adam Weizman

1530-1600 Therapeutic drug monitoring in IBD  
Sanjay Murthy

1600-1700 Panel discussion  
Charles Bernstein

FOR OUT-OF-TOWN GUESTS:
Rooms have been set aside at:
The Fort Garry Hotel, Spa & Conference Centre
222 Broadway, Winnipeg, MB R3C 0R3
Toll Free: 1 800 665 8088
Visit the website at www.fortgarryhotel.com
Please make your reservations prior to May 14, 2018
Refer to Group Code: 1113X3

Printing of this program was made possible by an unrestricted education grant from
AbbVie Canada Inc., Janssen Inc., Pfizer Canada Inc., Takeda Canada Inc. and Shire Canada
Learning Objectives

All Lectures will be 20 minutes with 10 minutes for discussion

- To learn approach to achalasia management
- To learn how to optimize treatment of GERD
- To understand presentation and treatment of eosinophilic esophagitis
- To understand surveillance of Barrett’s esophagus and managing dysplasia in Barrett’s
- To learn how to choose biological therapy in Crohn’s disease
- To learn how to choose biological therapy in ulcerative colitis
- To learn an approach to therapeutic drug monitoring for biologic treatment of IBD
- To understand how to optimize psychosocial support for patients with IBD
- To understand an approach to fistula disease in Crohn’s disease
- To develop an approach to complex IBD

Through this program the CanMEDS roles of medical expert, communicator, collaborator, health advocate and scholar will be covered.

Section 1 programs approved by the CAG for MOC Section 1 credits are eligible for conversion to AMA PRA Category 1 Credits™.

This event is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification program of the Royal College, approved by the Canadian Association of Gastroenterology (CAG).

Cover page illustrated from a drawing by William Biddle, Held in the University of Manitoba, Faculty of Medicine, Dean’s Office